| 1 |
NCT03359005 |
Recruiting |
Irinotecan and Temozolomide for Ewing Sarcoma |
|
- Drug: Irinotecan
- Drug: Temozolomide
|
Interventional |
Phase 2 |
- Peking University People's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Object response rate(ORR) at 12 weeks
- Progression-free survival(PFS)
- Overall survival(OS)
- Duration of response(DOR)
|
22 |
All |
Child, Adult, Senior |
NCT03359005 |
PKUPH-EWS-01 |
|
February 7, 2018 |
February 28, 2020 |
February 28, 2025 |
December 2, 2017 |
April 5, 2018 |
|
- Peking University People's Hospital
Beijing, Beijing, China
|
| 2 |
NCT01969942 |
Withdrawn |
A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma |
|
- Biological: allogeneic stem cell transplantation
- Drug: Clyclophosphamide
- Drug: Fludarabina
- (and 2 more...)
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Development of Grade 3-4 GVHD
|
0 |
All |
up to 30 Years (Child, Adult) |
NCT01969942 |
13.0176 |
ASCT |
April 2013 |
October 2016 |
October 2016 |
October 25, 2013 |
May 9, 2017 |
|
- Pediatric Hematology/Oncology University of Louisville
Louisville, Kentucky, United States
|
| 3 |
NCT02063022 |
Recruiting |
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma |
|
- Drug: Standard treatment (as per protocol ISG SSG III)
- Drug: Intensified chemotherapy
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event Free Survival (EFS)
- Disease Free Survival (DFS)
- Metastasis Free Survival
- Overall Survival (OS)
|
220 |
All |
up to 40 Years (Child, Adult) |
NCT02063022 |
ISG/AIEOP EW-1 |
EW-1 |
February 2009 |
December 2018 |
December 2018 |
February 14, 2014 |
April 11, 2018 |
|
- Centro di Riferimento Oncologico - Unit of Medical Oncology
Aviano, Pordenone, Italy - I.R.C.C. - Unit of Medical Oncology
Candiolo, Torino, Italy - Presidio Sanitario Gradenigo
Torino, TO, Italy - (and 10 more...)
|
| 4 |
NCT02511132 |
Active, not recruiting |
A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma |
|
- Biological: Vigil
- Drug: Temozolomide
- Drug: Irinotecan
|
Interventional |
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Adverse Events, Laboratory Assessments and Physical Examinations
- γIFN ELISPOT conversion rate from Blood Collected
|
22 |
All |
2 Years and older (Child, Adult, Senior) |
NCT02511132 |
CL-PTL-121 |
|
May 25, 2017 |
June 2018 |
December 2018 |
July 29, 2015 |
January 23, 2018 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Nicklaus Children's Hospital (Miami Children's Health System)
Miami, Florida, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - (and 3 more...)
|
| 5 |
NCT03029481 |
Available |
Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma |
|
|
Expanded Access |
|
- Jonsson Comprehensive Cancer Center
- NantCell, Inc.
|
Other / Industry |
|
|
|
All |
48 Years to 50 Years (Adult) |
NCT03029481 |
17-000019
JCCCID738 |
|
|
|
|
January 24, 2017 |
February 22, 2018 |
|
|
| 6 |
NCT01696669 |
Unknown † |
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults |
|
- Drug: Chemotherapy
- Procedure: Surgery
- Radiation: Radiotherapy
|
Interventional |
Phase 2 |
- Grupo Espanol de Investigacion en Sarcomas
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Objective response rate (ORR)
- Assessment of disease progression
- (and 3 more...)
|
43 |
All |
up to 40 Years (Child, Adult) |
NCT01696669 |
GEIS-21
2009-016027-62 |
|
April 2010 |
December 2016 |
December 2016 |
October 1, 2012 |
August 18, 2015 |
|
- Hospital Clínic de Barcelona
Barcelona, Spain - Hospital de la Santa Creu i Sant Pau
Barcelona, Spain - Hospital Vall d'Hebron
Barcelona, Spain - (and 6 more...)
|
| 7 |
NCT02736565 |
Active, not recruiting |
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma |
|
- Biological: pbi-shRNA™ EWS/FLI1 Type 1 LPX
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety: adverse events as assessed by CTCAE v4.0
- Efficacy measured by Clinical Response
|
4 |
All |
8 Years and older (Child, Adult, Senior) |
NCT02736565 |
CL-PTL-001 |
|
October 2016 |
September 2018 |
December 2019 |
April 13, 2016 |
February 22, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States - Mary Crowley Cancer Research Centers
Dallas, Texas, United States
|
| 8 |
NCT01858168 |
Recruiting |
Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma |
|
- Drug: Olaparib
- Drug: Temozolomide
- Drug: Irinotecan
|
Interventional |
Phase 1 |
- Massachusetts General Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine MTD of olaparib and irinotecan and/or temozolomide
- Evaluate safety and tolerability of olaparib/irinotecan and/or temozolomide combination
- Objective response in tumor dimensions to olaparib/irinotecan and/or temozolomide
- Explore variations in PARP activity and tumor characteristics
|
93 |
All |
16 Years and older (Child, Adult, Senior) |
NCT01858168 |
13-115 |
|
July 2013 |
July 2018 |
July 2019 |
May 21, 2013 |
November 13, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - Boston Children's Hospital
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - (and 2 more...)
|
| 9 |
NCT00987636 |
Recruiting |
Study in Localized and Disseminated Ewing Sarcoma |
|
- Drug: Zoledronic acid
- Drug: Busulfan
- Drug: Treosulfan
|
Interventional |
Phase 3 |
- University Hospital Muenster
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event free survival
- Overall survival
- safety and toxicity
- Quality of life
|
1163 |
All |
48 Months to 50 Years (Child, Adult) |
NCT00987636 |
108128
2008-003658-13 |
EWING2008 |
October 2009 |
March 2019 |
March 2019 |
October 1, 2009 |
May 20, 2016 |
|
- University Children´s Hospital, Pediatric Hematology and Oncology
Muenster, Germany
|
| 10 |
NCT01734863 |
Withdrawn |
Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients |
|
- Radiation: External Beam Radiotherapy
|
Interventional |
Phase 3 |
- Children's Cancer Hospital Egypt 57357
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- improved Local Relapse-free Survival (LRFS)
|
0 |
All |
1 Year to 18 Years (Child, Adult) |
NCT01734863 |
CCHE-BoneT002 |
|
September 2012 |
September 2022 |
December 2022 |
November 28, 2012 |
January 12, 2016 |
|
- Children's Cancer Hospital Egypt 57357
Cairo, Egypt
|
| 11 |
NCT02546544 |
Completed |
Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma |
- Relapsed Ewing Sarcoma
- Refractory Ewing Sarcoma
|
|
Interventional |
Phase 2 |
- University of Oxford
- European Organisation for Research and Treatment of Cancer - EORTC
- European Commission
- (and 2 more...)
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the pharmacodynamic effect of Linsitinib in the tumour (FDG uptake (SUV) responses in ES tumours using functional imaging 18FDG-PET-CT)
- To evaluate the safety and tolerability of Linsitinib (adverse events and laboratory abnormalities (CTCAE v4.0 grade, timing, seriousness and relatedness)
- Clinical outcome (PFS, DSS, ORR)
- Pharmacokinetics assays of following linsitinib treatment (Plasma concentrations of linsitinib)
|
40 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02546544 |
OCTO_038
2012-000616-28 |
LINES |
March 2014 |
July 15, 2016 |
July 15, 2016 |
September 11, 2015 |
March 22, 2017 |
|
- Universitè Lyon 1 Claude Bernard
Lyon, France - Pediatric Hematology and Oncology, University Hospital Münster
Münster, Germany - Istituti Ortopedici Rizzoli
Bologna, Italy - (and 2 more...)
|
| 12 |
NCT02044120 |
Recruiting |
ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma |
|
- Drug: niraparib
- Drug: Temozolomide
- Drug: Irinotecan
|
Interventional |
Phase 1 |
- Sarcoma Alliance for Research through Collaboration
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity and maximum tolerated dose
- Tumor response rate of patients treated with niraparib and temozolomide.
- Progression-free survival at 4 and 6 months of patients treated with niraparib and temozolomide
|
50 |
All |
13 Years and older (Child, Adult, Senior) |
NCT02044120 |
ESP1/SARC025 |
|
May 2014 |
September 2018 |
February 2019 |
January 23, 2014 |
April 11, 2018 |
|
- Children's Hospital of Los Angeles
Los Angeles, California, United States - National Cancer Institute
Bethesda, Maryland, United States - University of Michigan
Ann Arbor, Michigan, United States - (and 2 more...)
|
| 13 |
NCT01583543 |
Completed
Has Results |
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma |
|
|
Interventional |
Phase 2 |
- Massachusetts General Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate of Olaparib
- Progression-Free Survival
- Overall Survival
- Number of Participants Experiencing a Grade 3 or 4 Clinically Significant and Related Adverse Event
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT01583543 |
11-470 |
|
May 2012 |
January 2014 |
November 2014 |
April 24, 2012 |
May 19, 2017 |
May 19, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States - Brigham and Women's Hospital
Boston, Massachusetts, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States
|
| 14 |
NCT00568464 |
Terminated |
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT) |
|
- Drug: VCR, CTX, ADM; IFO, VP-16
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
10 |
All |
10 Years to 65 Years (Child, Adult) |
NCT00568464 |
VCD/IE-ESFT |
|
March 2007 |
May 2009 |
September 2009 |
December 6, 2007 |
July 7, 2009 |
|
- Fudan University Cancer Hospital
Shanghai, Shanghai, China
|
| 15 |
NCT02727387 |
Recruiting |
Protocol for the Treatment of Metastatic Ewing Sarcoma |
|
- Drug: TEMIRI
- Drug: ADM
- Drug: IFO
- (and 4 more...)
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Survival (OS)
- Event Free Survival (DFS)
- Safety - Incidence and grade of treatment-emergent Adverse Events
- Quality of life
|
70 |
All |
up to 40 Years (Child, Adult) |
NCT02727387 |
ISG/AIEOP EW-2 |
EW-2 |
May 2009 |
May 2018 |
May 2020 |
April 4, 2016 |
April 11, 2018 |
|
- Centro di Riferimento Oncologico - Unit of Medical Oncology
Aviano, Pordenone, Italy - I.R.C.C. - Unit of Medical Oncology
Candiolo, Torino, Italy - Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors
Bologna, Italy - (and 7 more...)
|
| 16 |
NCT00492141 |
Completed |
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma |
|
- Drug: Temozolomide
- Drug: L9-NC
|
Interventional |
Phase 1
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity Profile
- Number of Participants with Response According to Response Evaluation Criteria In Solid Tumors (RECIST)
|
10 |
All |
10 Years and older (Child, Adult, Senior) |
NCT00492141 |
2005-0889 |
|
June 2006 |
May 2007 |
September 2009 |
June 27, 2007 |
August 2, 2012 |
|
- U.T.M.D. Anderson Cancer Center
Houston, Texas, United States
|
| 17 |
NCT00339898 |
Completed |
Prognostic Value of a Positive RT-PCR Test in Patients With Ewing Sarcoma |
- Non-Metastatic Ewings Sarcoma
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
414 |
All |
2 Years to 30 Years (Child, Adult) |
NCT00339898 |
999904135
04-C-N135 |
|
March 12, 2004 |
|
January 13, 2015 |
June 21, 2006 |
April 17, 2018 |
|
- National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 18 |
NCT01864109 |
Recruiting |
Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma |
- Newly Diagnosed Ewing Sarcoma
|
- Drug: Cyclophosphamide
- Device: Doxorubicin
- Drug: Vincristine
- (and 6 more...)
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- event free survival of patients with localized disease
- event free survival of patients with metastatic disease
- adverse event profile
|
83 |
All |
1 Year to 40 Years (Child, Adult) |
NCT01864109 |
13-068 |
|
May 2013 |
May 2019 |
May 2019 |
May 29, 2013 |
August 3, 2017 |
|
- Memoral Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Commack
Commack, New York, United States - (and 3 more...)
|
| 19 |
NCT00038142 |
Terminated |
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients |
|
- Drug: Vincristine
- Drug: Doxorubicin
- Drug: Cyclophosphamide
- (and 2 more...)
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To see if treatment with the drugs, vincristine, doxorubicin, cyclophosphamide and dexrazoxane (VACdxr) given in high doses with or without ImmTher will help patients with Ewing's Sarcoma live longer.
|
46 |
All |
3 Years to 60 Years (Child, Adult) |
NCT00038142 |
ID97-198
NCI-2012-01285 |
|
November 1997 |
March 2016 |
March 2016 |
May 30, 2002 |
March 4, 2016 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 20 |
NCT00560235 |
Completed
Has Results |
Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors |
- Ewing's Sarcoma Family of Tumors
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate (ORR)
- Progression-Free Survival (PFS)
- Overall Survival (OS)
- (and 6 more...)
|
138 |
All |
10 Years and older (Child, Adult, Senior) |
NCT00560235 |
A4021020 |
|
March 2008 |
March 2010 |
October 2012 |
November 19, 2007 |
October 28, 2015 |
February 28, 2014 |
- Pfizer Investigational Site
Tampa, Florida, United States - Pfizer Investigational Site
Boston, Massachusetts, United States - Pfizer Investigational Site
Rochester, Minnesota, United States - (and 34 more...)
|
| 21 |
NCT03416517 |
Recruiting |
Anlotinib and Irinotecan for Ewing Sarcoma |
|
- Drug: Anlotinib Hydrochloride
- Drug: Irinotecan
|
Interventional |
Phase 2 |
- Peking University People's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Object response rate(ORR) at 12 weeks
- Progression-free survival(PFS)
- Overall survival(OS)
- (and 3 more...)
|
22 |
All |
3 Years to 18 Years (Child, Adult) |
NCT03416517 |
PKUPH-EWS-02 |
|
January 22, 2018 |
February 2020 |
December 2020 |
January 31, 2018 |
April 12, 2018 |
|
- Peking University First Hospital
Beijing, China - Peking University People's Hospital
Beijing, China - Peking University Shougang Hospital
Beijing, China - (and 2 more...)
|
| 22 |
NCT03011528 |
Recruiting |
First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years |
- Ewing Sarcoma Family of Tumors
|
- Drug: VDC-IE x2
- Drug: VDC-IE
- Drug: TEMIRI
- (and 4 more...)
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Anti-tumour effect of the treatment strategy assessed by the number of patients event-free survival (EFS) at 18 months
- Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the response rate of patients
- Anti-tumour effect of the dose-intensified induction chemotherapy assessed by the number of patients eligible for consolidation phase
- (and 8 more...)
|
45 |
All |
2 Years to 50 Years (Child, Adult) |
NCT03011528 |
IC 2015-13 CombinaiR3 |
CombinaiR3 |
December 2016 |
May 2020 |
December 2022 |
January 5, 2017 |
December 18, 2017 |
|
- Chr Felix Guyon
La Réunion, Saint Denis, France - Bordeaux Chu
Bordeaux, France - CHU Grenoble Alpes
Grenoble, France - (and 14 more...)
|
| 23 |
NCT01876303 |
Completed |
Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma |
- Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)
|
- Other: laboratory biomarker analysis
- Other: questionnaire administration
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Family-Based
- Time Perspective: Retrospective
|
- Main effect of gene polymorphisms
|
1650 |
All |
Child, Adult, Senior |
NCT01876303 |
AEPI10N5
NCI-2012-02210
U10CA098543 |
|
December 2012 |
July 2016 |
|
June 12, 2013 |
July 14, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
| 24 |
NCT01610570 |
Terminated
Has Results |
Mithramycin for Children and Adults With Solid Tumors or Ewing Sarcoma |
|
|
Interventional |
Phase 1
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD) of Mithramycin
- Number of Participants With Serious and Non-serious Adverse Events
- Objective Response Rate (Complete Response (CR) + Partial Response (PR))
- (and 10 more...)
|
8 |
All |
1 Year and older (Child, Adult, Senior) |
NCT01610570 |
120135
12-C-0135 |
|
May 10, 2012 |
May 21, 2014 |
May 21, 2014 |
June 4, 2012 |
March 2, 2018 |
February 15, 2016 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 25 |
NCT02657005 |
Recruiting |
TK216 in Patients With Relapsed or Refractory Ewing Sarcoma |
|
|
Interventional |
Phase 1 |
- Oncternal Therapeutics, Inc
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicities (DLTs)
- Maximum tolerated dose (MTD)
- Biologically effective and recommended Phase 2 dose (RP2D)
- (and 11 more...)
|
45 |
All |
10 Years and older (Child, Adult, Senior) |
NCT02657005 |
TK216-01 |
|
May 2016 |
September 2018 |
December 2018 |
January 15, 2016 |
April 17, 2018 |
|
- UCLA Jonsson Comprehensive Cancer Center
Los Angeles, California, United States - Children's Hospital of Colorado
Aurora, Colorado, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - UT MD Anderson Cancer Center
Houston, Texas, United States
|
| 26 |
NCT01780779 |
Unknown † |
Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults |
- Ewing Sarcoma
- Osteosarcoma
|
|
Observational |
|
- Universitaire Ziekenhuizen Leuven
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- tumor necrosis - therapy response
- Prognosis and outcome
|
25 |
All |
6 Years to 30 Years (Child, Adult) |
NCT01780779 |
FUBEO
S51516 |
FUBEO |
June 2009 |
June 2013 |
June 2014 |
January 31, 2013 |
January 31, 2013 |
|
- University Hospitals Leuven
Leuven, Belgium
|
| 27 |
NCT02472392 |
Completed |
Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma |
|
- Drug: Rabbit anti-thymocyte globulin
- Drug: Busulfan
- Drug: Melphalan
- (and 2 more...)
|
Interventional |
Phase 1 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicity assessed by safety labs and close monitoring from the study staff
|
10 |
All |
up to 30 Years (Child, Adult) |
NCT02472392 |
13.0167 |
Ewing/Allo |
April 2013 |
December 2016 |
December 2016 |
June 15, 2015 |
May 9, 2017 |
|
- University of Louisville
Louisville, Kentucky, United States
|
| 28 |
NCT00898053 |
Completed |
Study of Tumor Samples From Patients With Ewing Sarcoma |
- Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
- Other: laboratory biomarker analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Event-free survival
- Incidence of p53 mutations using the model of Sather and Sposto
- Incidence of p16 loss or deletion using the model of Sather and Sposto
|
200 |
All |
up to 50 Years (Child, Adult) |
NCT00898053 |
AEWS08B1
NCI-2009-00372
U10CA098543 |
|
September 2008 |
May 2016 |
May 2016 |
May 12, 2009 |
May 17, 2016 |
|
- Children's Oncology Group
Monrovia, California, United States
|
| 29 |
NCT00618813 |
Completed
Has Results |
Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors |
- Ewing Sarcoma of Bone
- Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
- Other: radiation therapy
- Other: therapeutic conventional surgery
- Drug: etoposide
- (and 6 more...)
|
Interventional |
Not Applicable |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Death
- Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Enrollment to Week 12
- Incidence Rate (Number of Participants) of Dose-limiting Toxicity (DLT) - Week 13 to Week 22
- (and 3 more...)
|
35 |
All |
up to 30 Years (Child, Adult) |
NCT00618813 |
AEWS07P1
NCI-2009-00371
CDR0000586282
U10CA098543
COG-AEWS07P1 |
|
March 2008 |
March 2010 |
|
February 20, 2008 |
September 25, 2014 |
February 10, 2014 |
- Children's Oncology Group
Monrovia, California, United States
|
| 30 |
NCT00824083 |
Completed |
Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment |
|
|
Observational |
|
- University Hospital Muenster
- German Federal Ministry of Education and Research
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- physical activity (SAM: step-activity-monitor)
- health-related quality of life (SF36, PEDQOL)
- functional status (TESS)
- psychological status (HADS, BIS-BAS)
|
950 |
All |
6 Years to 60 Years (Child, Adult) |
NCT00824083 |
01ER0807 |
|
July 2009 |
July 2015 |
July 2015 |
January 16, 2009 |
April 28, 2016 |
|
- Department of Pediatric Hematology and Oncology, University Children's Hospital
Muenster, North Rhine Westphalia, Germany - Motion Analysis Lab, Orthopedic Department, University Hospital
Münster, North Rhine Westphalia, Germany
|
| 31 |
NCT01313884 |
Terminated
Has Results |
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma |
- Bone Cancer
- Ewing's Sarcoma
|
- Drug: Irinotecan
- Drug: Vincristine
- Drug: Temozolomide
- (and 3 more...)
|
Interventional |
Phase 2 |
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (Partial and Complete Response)
- Progression-free Survival (PFS)
|
3 |
All |
13 Years and older (Child, Adult, Senior) |
NCT01313884 |
IRB-20323
SU-03082011-7559
SARCOMA0007 |
|
May 2011 |
July 2014 |
July 2014 |
March 14, 2011 |
November 24, 2017 |
February 2, 2017 |
- Stanford University School of Medicine
Stanford, California, United States
|
| 32 |
NCT00541411 |
Unknown † |
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma |
|
- Drug: Vincristine, Actinomycin-D, Ifosfamide
|
Interventional |
Not Applicable |
- King Faisal Specialist Hospital & Research Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
10 |
All |
Child, Adult, Senior |
NCT00541411 |
RAC#2031-065 |
|
June 2003 |
June 2013 |
June 2013 |
October 10, 2007 |
April 17, 2012 |
|
|
| 33 |
NCT03495921 |
Not yet recruiting
New |
Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma |
- Ewing Sarcoma
- Ewing Family of Tumors
- Ewing's Tumor Metastatic
- Ewing's Sarcoma Metastatic
|
- Biological: Vigil
- Drug: Irinotecan
- Drug: Temozolomide
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS)
- ELISPOT conversion rate
- Overall Survival (OS)
- Radiological Tumor Assessment
|
140 |
All |
2 Years and older (Child, Adult, Senior) |
NCT03495921 |
CL-PTL-130 |
|
June 15, 2018 |
December 31, 2021 |
July 1, 2022 |
April 12, 2018 |
April 12, 2018 |
|
|
| 34 |
NCT01882231 |
Terminated |
Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma |
- Osteosarcoma
- Paget's Disease
- Ewing Sarcoma
|
- Other: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
|
Interventional |
Not Applicable |
- Vanderbilt-Ingram Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Percent change in MRI metrics
- Progression-free survival
- Percent of tumor necrosed at surgical resection
- Percent change in tumor size
|
6 |
All |
13 Years and older (Child, Adult, Senior) |
NCT01882231 |
VICC SAR 1275
U01CA142565 |
|
March 2013 |
April 25, 2016 |
April 25, 2016 |
June 20, 2013 |
May 8, 2017 |
|
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
|
| 35 |
NCT03441360 |
Recruiting |
Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS) |
- Relapsed/Refractory Rhabdomyosarcoma
- Non-rhabdomyosarcoma Soft Tissue Sarcoma
- Ewing Sarcoma
|
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response
- Progression-free survival (PFS)
- Number of participants with any treatment-emergent (TE) serious adverse event (SAE)
- (and 6 more...)
|
30 |
All |
12 Months to 18 Years (Child, Adult) |
NCT03441360 |
E7389-G000-223 |
|
January 23, 2018 |
June 2020 |
January 2021 |
February 21, 2018 |
March 15, 2018 |
|
- Children's of Alabama
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Loma Linda University Cancer Center
Loma Linda, California, United States - (and 36 more...)
|
| 36 |
NCT00048984 |
Completed |
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma |
- Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
- Other: laboratory biomarker analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Time Perspective: Prospective
|
- Event-free survival
- Success rate in which biomarker analyses can be carried out
- Percent of the population on which biomarker analysis could be successfully conducted
- (and 2 more...)
|
637 |
All |
up to 50 Years (Child, Adult) |
NCT00048984 |
AEWS02B1
NCI-2012-02494
CDR0000257115
COG-AEWS02B1
NCI-03-C-0216
U10CA098543 |
|
January 2003 |
February 2013 |
|
January 27, 2003 |
June 24, 2013 |
|
- Children's Oncology Group
Arcadia, California, United States
|
| 37 |
NCT01585649 |
Completed |
PK/PD of XM22 in Children With Ewing Family of Tumors or Rhabdomyosarcoma |
- Ewing Family of Tumors, Rhabdomyosarcoma
|
|
Interventional |
Phase 1 |
- Merckle GmbH
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- PK: Area under the curve, Maximum observed serum concentration (Cmax), Rate constant associated with terminal phase, Mean Residence Time, Time to reach Cmax, and Apparent volume of distribution during terminal phase after non-intravenous administration
- PD:Absolute Neutrophil Count
|
21 |
All |
2 Years to 17 Years (Child) |
NCT01585649 |
XM22-07
2011-004742-18 |
|
July 2012 |
June 2014 |
April 2015 |
April 26, 2012 |
May 18, 2016 |
|
- Teva Investigational Site 0103
Plovdiv, Bulgaria - Teva Investigational Site 0101
Sofia, Bulgaria - Teva Investigational Site 0102
Varna, Bulgaria - (and 15 more...)
|
| 38 |
NCT00001335 |
Completed |
New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma |
- Ewing's Sarcoma
- Neuroblastoma
- Rhabdomyosarcoma
|
- Drug: ADR-529
- Drug: Topotecan
- Drug: G-CSF
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
90 |
All |
Child, Adult, Senior |
NCT00001335 |
930125
93-C-0125 |
|
April 1993 |
|
January 2002 |
November 4, 1999 |
March 4, 2008 |
|
- National Cancer Institute (NCI)
Bethesda, Maryland, United States
|
| 39 |
NCT00899990 |
Active, not recruiting |
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma |
- Askin Tumor
- Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
- Other: laboratory biomarker analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Banking of biological specimens, including associated demographic and clinical data
|
900 |
All |
up to 21 Years (Child, Adult) |
NCT00899990 |
AEWS07B1
NCI-2009-00370
COG-AEWS07B1
U10CA098543 |
|
February 2008 |
January 2100 |
January 2100 |
May 12, 2009 |
December 13, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 165 more...)
|
| 40 |
NCT00516295 |
Completed
Has Results |
Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma |
- Ewing Sarcoma of Bone
- Extraosseous Ewing Sarcoma
- Peripheral Primitive Neuroectodermal Tumor
- Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
- Drug: topotecan hydrochloride
- Drug: vincristine sulfate
- Drug: cyclophosphamide
- Biological: bevacizumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The Occurrence of Limiting Toxicity in an Eligible and Evaluable Patient.
- Time to Disease Progression in Patients Receiving VTC With or Without Bevacizumab
|
7 |
All |
1 Year to 29 Years (Child, Adult) |
NCT00516295 |
NCI-2009-00369
AEWS0521
U10CA098543 |
|
February 2008 |
August 2009 |
January 2010 |
August 15, 2007 |
September 2, 2014 |
September 2, 2014 |
- Children's Oncology Group
Philadelphia, Pennsylvania, United States
|
| 41 |
NCT01946529 |
Active, not recruiting
Has Results |
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors |
- Desmoplastic Small Round Cell Tumor
- Ewing Sarcoma of Bone or Soft Tissue
- Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
- Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
|
- Drug: vincristine
- Drug: doxorubicin
- Drug: cyclophosphamide
- (and 8 more...)
|
Interventional |
Phase 2 |
- St. Jude Children's Research Hospital
- University of Tennessee Health Science Center
- University of Florida
- Nemours Children's Clinic
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response to Window Therapy (2 Courses) for Group B (High-risk) - ESFT Participants
- Overall Survival
- Progression-free Survival
- (and 2 more...)
|
24 |
All |
up to 25 Years (Child, Adult) |
NCT01946529 |
ESFT13
NCI-2013-01657 |
|
December 27, 2013 |
August 2015 |
July 2026 |
September 19, 2013 |
October 19, 2017 |
October 19, 2016 |
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 42 |
NCT01365949 |
Completed |
Biomarker in Tissue Samples From Patients With Ewing Sarcoma |
|
- Genetic: microarray analysis
- Genetic: protein analysis
- Other: immunohistochemistry staining method
- Other: laboratory biomarker analysis
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Frequency of INI1 protein loss in Ewing Sarcoma
|
40 |
All |
up to 120 Years (Child, Adult, Senior) |
NCT01365949 |
AEWS11B1
COG-AEWS11B1
NCI-2011-02857 |
|
May 2011 |
July 2016 |
|
June 3, 2011 |
July 11, 2016 |
|
|
| 43 |
NCT01480518 |
Completed |
Biomarkers in Tissue Samples From Patients With Ewing Sarcoma |
|
- Genetic: DNA analysis
- Genetic: comparative genomic hybridization
- Genetic: gene expression analysis
- (and 4 more...)
|
Observational |
|
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
|
166 |
All |
up to 50 Years (Child, Adult) |
NCT01480518 |
AEWS11B2
COG-AEWS11B2
NCI-2012-00083 |
|
December 2011 |
January 2012 |
January 2012 |
November 29, 2011 |
May 12, 2015 |
|
|
| 44 |
NCT01210209 |
Unknown † |
Study of Blood Samples From Patients With Ewing Sarcoma and Their Relatives |
|
- Other: genome-wide association study
|
Observational |
|
- Institut Curie
- National Cancer Institute (NCI)
|
Other |
|
- Identification and characterization of susceptibility genes in patients with Ewing sarcoma
|
600 |
All |
Child, Adult, Senior |
NCT01210209 |
CDR0000683940
CLCC-IC-2009-02
2009-A00558-49
EU-21064 |
|
September 2009 |
September 2011 |
|
September 28, 2010 |
August 26, 2013 |
|
- Institut Curie Hopital
Paris, France
|
| 45 |
NCT00276692 |
Completed |
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma |
|
- Drug: irinotecan hydrochloride
|
Interventional |
Phase 2 |
- Children's Cancer and Leukaemia Group
- National Cancer Institute (NCI)
|
Other |
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response as measured by MRI following course 2
|
35 |
All |
up to 19 Years (Child, Adult) |
NCT00276692 |
CCLG-ET-2003-04
CDR0000454550
EU-20582 |
|
August 2003 |
September 2008 |
July 2009 |
January 13, 2006 |
June 26, 2013 |
|
- Our Lady's Hospital for Sick Children Crumlin
Dublin, Ireland - Birmingham Children's Hospital
Birmingham, England, United Kingdom - Institute of Child Health at University of Bristol
Bristol, England, United Kingdom - (and 18 more...)
|
| 46 |
NCT00470275 |
Completed
Has Results |
Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma |
|
|
Interventional |
Phase 2 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
10 |
All |
up to 30 Years (Child, Adult) |
NCT00470275 |
AEWS0621
CDR0000542650
COG-AEWS0621 |
|
May 2007 |
August 2008 |
December 2013 |
May 7, 2007 |
October 20, 2014 |
November 1, 2013 |
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham
Birmingham, Alabama, United States - Arizona Cancer Center at University of Arizona Health Sciences Center
Tucson, Arizona, United States - Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - (and 70 more...)
|
| 47 |
NCT02243605 |
Recruiting |
Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma |
- Metastatic Ewing Sarcoma
- Metastatic Osteosarcoma
- Recurrent Ewing Sarcoma
- (and 7 more...)
|
- Drug: Cabozantinib S-malate
- Other: Laboratory Biomarker Analysis
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Non-progression, defined as complete response (CR), partial response (PR), or stable disease (osteosarcoma)
- Objective response, defined as CR or PR (osteosarcoma)
- Objective response, defined as CR or PR (Ewing sarcoma)
- (and 4 more...)
|
90 |
All |
12 Years and older (Child, Adult, Senior) |
NCT02243605 |
NCI-2014-01927
CABONE
9620 |
|
December 19, 2014 |
June 30, 2019 |
|
September 18, 2014 |
March 5, 2018 |
|
- Institut Bergonie Cancer Center
Bordeaux, France - Centre Georges-Francois Leclerc
Dijon, France - Centre Oscar Lambert
Lille, France - (and 8 more...)
|
| 48 |
NCT00002516 |
Unknown † |
Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma |
|
- Biological: dactinomycin
- Drug: cyclophosphamide
- Drug: doxorubicin hydrochloride
- (and 7 more...)
|
Interventional |
Phase 3 |
- University Hospital Muenster
- Medical Research Council
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
|
|
All |
up to 35 Years (Child, Adult) |
NCT00002516 |
CDR0000078196
GER-GPOH-EICESS-92
MRC-EICESS-92
EU-92030
EU-205116
UKCCSG-ET1993-02 |
|
July 1992 |
|
|
May 5, 2004 |
September 17, 2013 |
|
- Royal Victoria Infirmary
Newcastle-upon-Tyne, England, United Kingdom
|
| 49 |
NCT00334867 |
Withdrawn |
Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma |
|
- Drug: cyclophosphamide
- Drug: dexrazoxane hydrochloride
- Drug: doxorubicin hydrochloride
- (and 6 more...)
|
Interventional |
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Primary Purpose: Treatment
|
- Event-free survival
- Survival form study enrollment
|
0 |
All |
up to 50 Years (Child, Adult) |
NCT00334867 |
AEWS0531
COG-AEWS0531
CDR0000483611 |
|
December 2005 |
January 2006 |
|
June 8, 2006 |
June 28, 2013 |
|
|
| 50 |
NCT00743496 |
Completed |
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma |
- Neuroblastoma
- Melanoma
- Osteosarcoma
- Ewing Sarcoma
|
- Biological: Anti-GD2 antibody
|
Interventional |
Phase 1 |
- St. Jude Children's Research Hospital
- Evan T.J. Dunbar Neuroblastoma Foundation
- Duke University
- (and 3 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine maximum tolerated dose and dose-limiting toxicity of the humanized monoclonal anti-GD2 antibody, hu14.18K322A, in research participants with neuroblastoma, osteosarcoma, Ewing sarcoma and melanoma.
|
50 |
All |
up to 21 Years (Child, Adult) |
NCT00743496 |
SJGD2
ED FDN
NCI-2011-01150 |
|
October 8, 2008 |
April 1, 2014 |
April 18, 2014 |
August 28, 2008 |
August 17, 2017 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
Create an RSS feed from your search for:
Download the search results for: